-
A New Generation of Fully Human anti-CTLA-4 Heavy Chain Only Antibody
-
BCMA x CD3 Bispecific Antibody – A novel HBICE™-based Molecule with Efficient Tumor Killing and Minimal Cytokine Release
-
HBM1007 – A Highly Potent Anti-CD73 mAb Candidate For Mono And Combination IO Therapy
-
Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy
-
HBM1022, a Novel Anti-CCR8 Antibody, Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity
-
HCAb Based Bispecific Immune Cell Engager (HBICE) Platform Enables Fast And Convenient Generation of the Next Generation Bispecific Antibodies with High Potency, Promising Safety Profiles and Excellent Developability
-
Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy
-
Development of fully human T-cell engaging bispecific antibodies targeting B7H4
-
Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer
-
Cell Engager Summit Exclusive Speaker Interview
-
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
-
A human monoclonal antibody blocking SARS-CoV-2 infection
-
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
-
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
-
SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers
-
Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study
-
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China